ASAS40 and 20 responses to biologic DMARDs (bDMARDs) in ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpA) in phase III clinical trials.
Direct comparison is limited given that there are no head-to-head studies comparing biologics. Partly adapted from Sieper et al.5
DMARD, disease modifying antirheumatic drug.